COUR Pharmaceuticals Development Co.
Latest round
- Series B
Last raised
- Jun 2026
Total raised
- $155M
Investors
- 8
About COUR Pharmaceuticals Development Co.
Based in Skokie, Illinois, US, and founded in 2015 by John J., Inc. is a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies to reprogram the immune system for immune-mediated diseases. Dannielle Appelhans currently serves as President and CEO. Cour Pharmaceuticals Development Company, Inc. has developed a proprietary antigen-specific immune tolerance nanoparticle platform (CNP platform), designed to reprogram the immune system to induce tolerance to disease-driving antigens while preserving normal immune function. The company's product pipeline includes CNP-103, a biodegradable nanoparticle encapsulating four recombinant proteins covering more than 95% of antigens driving type 1 diabetes (T1D), currently in a Phase 1b/2a clinical trial and granted FDA Fast Track Designation; CNP-104, a biodegradable nanoparticle encapsulating PDC-E2 for the treatment of primary biliary cholangitis (PBC), granted FDA Fast Track and Orphan Drug Designations; CNP-106, an antigen-specific investigational therapeutic for myasthenia gravis, granted FDA Orphan Drug Designation; CNP-105, an investigational therapeutic for immune thrombocytopenia (ITP), designed to restore normal platelet levels; CNP-107, an antigen-specific investigational therapeutic for vitiligo; and CNP-108, a biodegradable nanoparticle encapsulating AAV protein for gene therapy and protein replacement applications. In partnered programs, the company is developing CNP-101/TAK-101, a biodegradable nanoparticle encapsulating gliadin proteins for the treatment of celiac disease, partnered with Takeda and granted FDA Fast Track Designation; and CNP-201, a biodegradable nanoparticle encapsulating peanut protein for the treatment of peanut allergy. As of June 2026, the company plans to use the Series B proceeds to advance the clinical development of CNP-103 through its Phase 1b/2a trial for type 1 diabetes, and to seek partners for the continued clinical development of CNP-104 for primary biliary cholangitis and CNP-106 for myasthenia gravis
Who invested in COUR Pharmaceuticals Development Co.
8 investors across 2 rounds
See all investors in COUR Pharmaceuticals Development Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about COUR Pharmaceuticals Development Co.
Who invested in COUR Pharmaceuticals Development Co.?
COUR Pharmaceuticals Development Co. has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has COUR Pharmaceuticals Development Co. raised?
COUR Pharmaceuticals Development Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did COUR Pharmaceuticals Development Co. last raise money?
COUR Pharmaceuticals Development Co.'s most recent round on record is a Series B, in Jun 2026.
What does COUR Pharmaceuticals Development Co. do?
Based in Skokie, Illinois, US, and founded in 2015 by John J.
Where is COUR Pharmaceuticals Development Co. headquartered?
COUR Pharmaceuticals Development Co. is headquartered in Skokie, US.
Which VCs invest in companies like COUR Pharmaceuticals Development Co.?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at COUR Pharmaceuticals Development Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like COUR Pharmaceuticals Development Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.